An Evaluation Synthesis of US AIDS Drug Assistance Program Policy


US Congress passed the CARE Act in 1990 in response to a dramatically growing need for resources to combat the AIDS epidemic. One of the programs contained in the Act was the AIDS Drug Assistance Program (ADAP), a federally-funded but state-maintained and managed program primarily concerned with providing medication for low-income HIV/AIDS patients. While ADAP programs across the country reached one-third of all patients in 2007, these programs are now in budgetary danger due to the economic recession, state budgetary constraints, the rising cost of healthcare generally, and longer life expectancies associated with current highly active antiretroviral therapy (HAART). This paper first evaluates the current state of ADAP, its strengths and weaknesses, and examines its sustainability in the short term if short-term measures are taken. Concluding that such measures would not lead to long-term sustainability, this paper then argues for a long-term solution to ADAP’s current problems, namely a national, centralized ADAP standard for budgetary and administrative matters. Such a program would increase the long-term sustainability and effectiveness of current ADAP programs by employing more efficient, standard policies and allowing larger, wholesale purchases of costly HAART medications. Moreover, a national policy would address the disparity that currently exists in ADAP programs today with regard to both minorities and those on the waiting lists for treatment. The institution of a national ADAP program would certainly face many political hurdles. Consequently, this paper also looks to a recent political dispute, the enactment of the Affordable Care Act (ACA), for guidance. Using the passage of the ACA as an example could light the path for passage of a national ADAP standard. Ultimately, this would lead to a more effective and sustainable program for HIV/AIDS patients in the United States.

Share and Cite:

M. Horneffer and Y. Yang, "An Evaluation Synthesis of US AIDS Drug Assistance Program Policy," World Journal of AIDS, Vol. 3 No. 2, 2013, pp. 85-91. doi: 10.4236/wja.2013.32012.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] US Department of Health and Human Services, “Going the Distance: The Ryan White HIV/AIDS Program. 20 Years of Leadership, A Legacy of Care,” 2010. downloads/samples/writing/ Going-the-Distance-20-years-of-the-Ryan-White- HIV-AIDS-Program.pdf
[2] M. Johri, D. A. Paltiel, S. J. Goldie and K. A. Freedberg, “State AIDS Drug Assistance Programs: Equity and Efficiency in an Era of Rapidly Changing Treatment Standards,” Medical Care, Vol. 40, No. 5, 2002, pp. 429-441.
[3] D. P. Goldman, J. Bhattacharya, A. A. Leibowitz, G. F. Joyce, M. F. Shapiro and S. A. Bozzette, “The Impact of State Policy on the Costs of HIV Infection,” Medical Care Research and Review, Vol. 58, No. 1, 2001, pp. 31-53.
[4] B. R. Schackman, K. A. Gebo, R. P. Walensky, E. Losina, T. Muccio, P. E. Sax, et al., “The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States,” Medical Care, Vol. 44, No. 11, 2006, pp. 990-997. doi:10.1097/01.mlr.0000228021.89490.2a
[5] Kaiser Family Foundation, “2009 National ADAP Monitoring Project Annual Report,” The Henry J. Kaiser Family Foundation, 2009.
[6] R. P. Walensky, A. D. Paltiel and K. A. Freedman. “AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States,” Clinical Infectious Diseases, Vol. 35, No. 5, 2002, pp. 606-610. doi:10.1086/341903
[7] S. Morin, “Responding to Racial and Ethnic Disparities in Use of HIV Drugs: Analysis of State Policies,” Public Health Reports, Vol. 117, No, 3, 2002, pp. 263-272.
[8] A. A. Leibowitz and N. Sood, “Market Power and State Costs of HIV/AIDS Drugs,” International Journal of Health Care Finance and Economics, Vol. 7, No. 1, 2007, pp. 59-71. doi:10.1007/s10754-007-9012-0
[9] J. Kahn, “Access to and Use of HIV Antiretroviral Therapy: Variation by Race/ethnicity in Two Public Insurance Programs in the US,” Public Health Reports, Vol. 117, No. 3, 2002, pp. 252-262.
[10] B. P. Linas, H. Zheng, E. Losina, A. Rockwell, R. P. Walensky, K. Cranston, et al., “Optimizing Resource Allocation in United States AIDS Drug Assistance Programs,” Clinical Infectious Diseases, Vol. 43, No. 10, 2006, pp. 1357-1364. doi:10.1086/508657
[11] J. McCarter, “Obamacare Unpopular, Unless It’s Not Called Obamacare,” Daily Kos, 2012.
[12] Pew Research Center, “Health Care Proposals Remain Hard to Follow,” Pew Research Center for the People and the Press, 2009.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.